KB

Kevin Bitterman

Partner at Atlas Venture

Cambridge, Massachusetts

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $10,000,000.00

  • Max Investment:

    $50,000,000.00

  • Target Investment:

    $25,000,000.00

Skills

Venture Capital
Biotechnology
Medical Devices
Pharmaceutical Industry
Lifesciences
Technology Transfer
Commercialization
Molecular Biology
Biopharmaceuticals
Drug Discovery
Clinical Development
Clinical Trials
Genomics
Cell Biology
Start-ups
Immunology
Vaccines
Oncology
Infectious Diseases
Drug Development

Education

Lists including Kevin

AP
AO
AS
AN

Based in UK

1884 people

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Investments

Disc Medicine

Series A

Total Funding: $440M

Remix Therapeutics

Seed

Total Funding: $210M

Mariana Oncology

Series A

Total Funding: $250M

Curie Therapeutics

Series A

Total Funding: $75M

Akero Therapeutics

Series A

Total Funding: $140M

Visterra

Seed

Total Funding: $120M

Neuronetics

Series E

Total Funding: $170M

Morphic Therapeutic

Series A

Total Funding: $140M

Kala Pharmaceuticals

Private Equity

Total Funding: $110M

Pulmatrix

Series A

Total Funding: $58M

Work Experience

AV
Atlas Venture

2017

  • Partner

    2017

JB
Judo Bio

2022

  • Board of Directors

    2022

RT
Remix Therapeutics

2019

  • Board of Directors

    2019

nB
nChroma Bio

2020

  • Board of Directors

    2020

KT
Kinaset Therapeutics

2020

  • Board of Directors

    2020

DM
Disc Medicine

2017

  • Board Of Directors

    2017

IS
Isabella Stewart Gardner Museum

2017

  • Member Board of Trustees

    2017

MO
Mariana Oncology

2021 - 2024

  • Board of Directors

    2021 - 2024

NE
New England Venture Capital Association

2013 - 2023

  • Board Member

    2013 - 2023

AT
Akero Therapeutics

2018 - 2021

  • Board of Directors

    2018 - 2021